Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio Ltd., a clinical stage biopharmaceutical company developing oral peptide therapies, has appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer. Dr. Camisasca brings over 30 years of global pharmaceutical experience and will strengthen Entera's clinical and late-stage development capabilities as the company prepares to initiate P…